Brain zaps are sudden, electric shock-like sensations in the head that many people experience when they stop or reduce an antidepressant, particularly one with a short half-life like paroxetine, venlafaxine, or duloxetine. The sensation is brief — typically one to three seconds — and is often triggered by head movements or eye movements, though it can happen spontaneously as well. Brain zaps are harmless in the medical sense, but they can be disruptive enough to interfere with daily life, and they are one of the clearest signals that an antidepressant dose was reduced too quickly or stopped too abruptly.
The good news is that brain zaps are preventable with a gradual, properly designed taper, and they resolve on their own once the nervous system adjusts to the medication change — or immediately if the previous dose is briefly restored.
What do brain zaps feel like?
People describe brain zaps in strikingly consistent terms across different antidepressants: sudden electric shocks in the head, a sensation like the brain is rebooting, or a momentary jolt that feels like touching a live wire. The sensation is difficult to articulate precisely, but the phrase "electric shock" appears repeatedly in patient reports, and most people who have experienced it recognize the description immediately (Akdogan, 2026).
Brain zaps often come with other sensory disturbances — mild dizziness, brief visual disturbances, a sensation of imbalance, or nausea. In one case series documenting brain zaps following discontinuation of paroxetine, venlafaxine, and duloxetine, patients reported between fifteen and thirty episodes daily during the peak of discontinuation symptoms, each lasting one to three seconds (Akdogan, 2026).
The sensation is not dangerous — it does not indicate nerve damage or a seizure — but it can be distressing and disorienting, especially when it happens dozens of times a day.
Why do brain zaps happen when you stop an antidepressant?
Brain zaps are part of antidepressant discontinuation syndrome, the cluster of symptoms that can appear when an SSRI or SNRI is stopped or reduced too quickly. The mechanism is not fully understood, but the leading explanation involves the sudden drop in serotonin signaling after weeks, months, or years of elevated levels.
When you take an SSRI or SNRI, the medication increases serotonin availability in the brain, and the nervous system adapts to that elevated baseline — serotonin receptors down-regulate, and other neurotransmitter systems adjust accordingly. When the medication is reduced abruptly, serotonin levels drop faster than the nervous system can re-adapt, and the resulting neurochemical instability is thought to produce the sensory and vestibular disruptions people experience as brain zaps and dizziness (Renoir, 2013).
Some researchers have proposed that cholinergic rebound — an overactivity of acetylcholine signaling after the medication is withdrawn — may also contribute, particularly with paroxetine, which has anticholinergic properties that other SSRIs lack. But the exact pathways remain uncertain, and what is clear is that the faster the medication leaves your system, the more likely discontinuation symptoms are to occur.
Which antidepressants are most likely to cause brain zaps?
The risk of brain zaps correlates closely with a medication's half-life — the time it takes for half of the drug to clear from your bloodstream. Antidepressants with short half-lives leave your system quickly, which means the drop in serotonin signaling is abrupt, and that abruptness is what triggers discontinuation symptoms.
Venlafaxine (Effexor) has the highest reported rate of brain zaps among commonly prescribed antidepressants. According to a 2019 review, venlafaxine's "extremely short half-life" can cause withdrawal symptoms to appear "as early on as after a delayed dose," and the WHO pharmacovigilance database identified venlafaxine as having more than double the expected rate of withdrawal-related reports compared to other antidepressants (Henssler et al., 2019).
Paroxetine (Paxil) also poses high risk. In one analysis of SSRI discontinuation cases, paroxetine was involved in sixty-five percent of reported discontinuation syndromes, compared to only seven percent for fluvoxamine despite both medications having similar half-lives — suggesting that paroxetine's additional anticholinergic effects amplify withdrawal symptoms beyond what half-life alone would predict (Renoir, 2013).
Duloxetine (Cymbalta), another SNRI, also appears frequently in brain zap reports, particularly when stopped abruptly.
Sertraline (Zoloft) and escitalopram (Lexapro) have moderate discontinuation risk — higher than fluoxetine but lower than paroxetine or venlafaxine. Both have elimination half-lives around one day, which means discontinuation symptoms can occur if the medication is stopped suddenly, but they are generally less severe and less frequent than with the shorter-acting agents.
Fluoxetine (Prozac) has the lowest risk of any commonly prescribed SSRI or SNRI. Its half-life of four to six days, combined with its active metabolite's half-life of up to sixteen days, means fluoxetine tapers itself gradually even if you stop taking it abruptly — the medication lingers in your system for weeks, which minimizes the abrupt serotonin drop that triggers discontinuation symptoms. The 2019 review concluded that fluoxetine is "particularly unproblematic, even in the case of abrupt discontinuation" (Henssler et al., 2019).
Bupropion (Wellbutrin), which is not an SSRI or SNRI, rarely causes brain zaps because it works on dopamine and norepinephrine rather than serotonin.
How common are brain zaps and other discontinuation symptoms?
Estimates of overall discontinuation syndrome prevalence vary, but approximately fifteen percent of people who stop an SSRI or SNRI experience some form of withdrawal symptoms, with the rate climbing higher for short-half-life medications and for people who have been on the medication for a long time (Akdogan, 2026).
Brain zaps specifically are reported by roughly half of people who experience sensory symptoms during discontinuation, though not everyone uses that exact term — some describe it as dizziness, electric shocks, or head rushes, all of which may be referring to the same phenomenon.
The symptoms typically appear within one to seven days after stopping or reducing the medication, and they usually resolve within one to two weeks if the medication is not restarted. If the dose is restored to the previous level, the symptoms often disappear within a day or two, which is both diagnostic — it confirms the symptoms were discontinuation-related rather than relapse — and immediately relieving.
How do you tell brain zaps from relapse of depression or anxiety?
This is one of the most clinically important distinctions, because acting on the wrong interpretation leads to different outcomes. If discontinuation symptoms are mistaken for relapse, a medication that could have been stopped is restarted indefinitely. If relapse is mistaken for withdrawal, someone who needs ongoing treatment stops their medication prematurely.
The differences are clearest in timing, symptom type, and response to a small dose change.
Discontinuation symptoms — including brain zaps — appear within days of a dose reduction, include physical or sensory features like dizziness, nausea, electric shock sensations, and flu-like feelings, and settle quickly if the previous dose is briefly restored. A genuine return of depression or anxiety builds over weeks, looks like the original illness rather than a new set of physical symptoms, and does not shift with a small dose adjustment (Renoir, 2013).
Making that distinction correctly is the main reason to taper under supervision rather than alone. Supervised tapering allows a prescriber to observe the pattern of symptoms, adjust the pace of the taper if needed, and distinguish between discontinuation syndrome and relapse based on timing and response.
What should you do if you are experiencing brain zaps?
If you are already experiencing brain zaps, the safest step is to contact your prescriber. Do not try to manage it on your own by stopping the medication entirely or by restarting a dose without guidance — both can complicate the situation.
The immediate intervention depends on severity. If the brain zaps are mild and infrequent, and you are otherwise tolerating the taper, your prescriber may recommend holding at the current dose for a longer period before the next reduction. If the symptoms are frequent or disruptive, the usual approach is to go back to the previous dose — the one before the reduction that triggered the symptoms — hold there until the symptoms resolve, and then resume the taper at a slower pace with smaller steps.
In some cases, particularly with very short-half-life medications like venlafaxine or paroxetine, switching to fluoxetine as a bridge medication can smooth the discontinuation process — fluoxetine's long half-life allows the nervous system to adjust more gradually. That strategy was used successfully in one of the paroxetine cases documented in the 2026 case series (Akdogan, 2026).
What you should not do is push through severe discontinuation symptoms in the belief that they are temporary and harmless. While brain zaps are not medically dangerous, they are a signal that the taper is too fast for your nervous system to keep up, and continuing at that pace increases the risk that you will abandon the taper entirely and restart the medication out of necessity.
How can you prevent brain zaps when stopping an antidepressant?
The most effective prevention is a gradual taper designed around the medication's half-life and the dose-response curve. That means progressively smaller reductions as the dose gets lower, not equal steps all the way down to zero.
This approach is called hyperbolic tapering, and it is based on the finding that the relationship between dose and effect is not linear — cutting a high dose in half removes a small amount of serotonin transporter occupancy, but cutting a low dose in half removes a much larger share, and the final step from the lowest dose to zero removes the most. A well-designed taper matches the size of each reduction to the shape of that curve, which prevents the abrupt drop in effect that triggers discontinuation symptoms (Horowitz & Taylor, 2019).
You can read more about that method in the site's post on hyperbolic tapering.
How long a taper takes depends on the medication, the dose, how long you have been on it, and whether you have had withdrawal symptoms on a previous attempt. Someone who has taken an SSRI for a few months at a low dose may need only a few weeks. Someone who has taken one for years, or who is on a short-half-life medication like paroxetine or venlafaxine, may need many months, with pauses along the way if symptoms appear.
The key principle is that the pace is set by your response to each step, not by a calendar. If a reduction produces symptoms, the step was too large, and the answer is to hold or go back rather than to push through. That is the reason a taper is a plan revised at each visit rather than a schedule handed over at the first one.
When should you not taper off an antidepressant?
Brain zaps and discontinuation syndrome are reasons to taper more carefully, not reasons to avoid tapering entirely if stopping the medication is the right clinical decision. But they are also a reminder that stopping is not always the right decision.
If the medication is working — if it is controlling symptoms, improving function, and not causing intolerable side effects — there is no medical reason to stop it, and for many people staying on is the better choice. The decision to come off an antidepressant is separate from the method, and it should be made during an evaluation that considers why the medication was started, whether the underlying condition has resolved or is being managed in other ways, past history of relapse, and what the plan is if symptoms return.
If the reason for stopping is side effects, cost, or a sense that the medication is not working as well as it used to, those are all legitimate concerns — but they are different from "I have been on it long enough and want to be off," which may or may not be clinically sound depending on the history.
The evaluation is where that decision gets made, and the taper is what happens after the decision is clear.
Getting started
Laura Gabriel, PMHNP-BC, provides supervised antidepressant tapering and medication management for adults by secure telehealth video to people located in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky. The initial evaluation clarifies whether tapering is appropriate, and the follow-up visits adjust the pace of the taper based on your response — there is no fixed schedule, and if discontinuation symptoms appear, the plan changes accordingly. You can learn more about tapering off antidepressants or send a message to get started. Initial evaluations are typically $250–$350 before insurance reimbursement, and follow-up visits are $125–$200. Coverage details are on the insurance page.
Do not reduce or stop an antidepressant on your own without guidance from the prescriber who knows your medication, dose, and history. This post is general information, not a taper plan. If you are in crisis or immediate danger, call 911. For urgent support at any hour, call or text 988 (Suicide & Crisis Lifeline).
References
Akdogan, T. I. (2026). Brain zaps after antidepressant discontinuation: Heterogeneous responses across paroxetine, venlafaxine, and duloxetine—a three-case letter. Dusunen Adam Journal of Psychiatry and Neurological Sciences, 39(2), 162–164. https://pmc.ncbi.nlm.nih.gov/articles/PMC13289696/
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019). Antidepressant withdrawal and rebound phenomena. Deutsches Ärzteblatt International, 116(20), 355–361. https://pmc.ncbi.nlm.nih.gov/articles/PMC6637660/
Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry, 6(6), 538–546. https://pubmed.ncbi.nlm.nih.gov/30850328/
Renoir, T. (2013). Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved. Frontiers in Pharmacology, 4, 45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3627130/